In this issue:
- Ethnic and socioeconomic disparities in DMT use in NZ
- Clinic follow-up visits do not affect mortality in pwMS
- Finite-course vs standard interval dosing of ocrelizumab in relapsing MS
- Impact of NMOSD on employment rates
- Impact of different DMT reimbursement policies in Slovenia and Croatia
- PIRA in the era of high efficacy treatments
- Types of pain in pwMS
- Disease course from onset of MS to secondary progression
- aHSCT affects long-term PIRA in patients with aggressive MS
- MS fatigue post high-efficacy treatment
Please login below to download this issue (PDF)